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Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major causes of chronic hepatitis infection
(CHI). This longitudinal cohort study investigated the association of CHI with hepatic and extrahepatic cancer
development in Taiwan.
Methods: Patients with HBV infection and HCV infection were identified from the Taiwan National Health Insurance
Research Database. A Cox proportional hazard model was used to calculate hazard ratios (HRs) and 95 %
confidence intervals (CIs) for determining the association between CHI and cancer development.
Results: The patients with HBV infection exhibited an increased risk of colorectal cancer (HR: 1.36, 95 % CI: 1.09–1.70),
liver cancer (HR: 21.47, 95 % CI: 18.0–25.6), gallbladder and extrahepatic bile duct cancer (HR: 2.05, 95 % CI: 1.07–3.91),
pancreatic cancer (HR: 2.61, 95 % CI: 1.47–4.61), kidney cancer (HR: 1.72, 95 % CI: 1.10–2.68), ovarian cancer (HR: 2.31,
95 % CI: 1.21–4.39), and non-Hodgkin’s lymphoma (HR: 2.10, 95 % CI: 1.25–3.52). The patients with HCV infection
exhibited an increased risk of liver cancer (HR: 25.10, 95 % CI: 20.9–30.2), gallbladder and extrahepatic bile duct cancer
(HR: 2.60, 95 % CI: 1.42–4.73), ovarian cancer (HR: 5.15, 95 % CI: 1.98–13.4), and non-Hodgkin’s lymphoma (HR: 2.30,
95 % CI: 1.34–3.96).
Conclusion: The present population-based study revealed that in addition to its association with primary liver cancer,
CHI is associated with an increased risk of extrahepatic cancer.
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Background
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are
the major causes of chronic hepatitis infection (CHI).
Approximately 2 billion people worldwide have been in-
fected with HBV, and 360 million people are currently
chronic carriers [1]. HCV has been estimated to infect
approximately 185 million people worldwide, with the
highest prevalence in Central and East Asian, North
African, and Middle Eastern regions [2], and more than
75 % of chronic HBV carriers reside in Asian countries, in-
cluding Taiwan [3]. The prevalence of hepatitis B surface
antigen (HBsAg) carriers in Asia is estimated to be 8–12 %
[4]. Patients with CHI are at an increased risk of liver fibro-
sis, liver cirrhosis, and hepatocellular carcinoma [5, 6].
Epidemiological studies have reported an association be-
tween CHI and primary liver cancer development [6–9].
Furthermore, some studies have revealed an association
between CHI and the development of extrahepatic cancers
such as pancreatic cancer [10], gallbladder and extrahe-
patic bile duct cancer [11], intrahepatic cholangiocarci-
noma, and non-Hodgkin’s lymphoma [12–15]. A study in
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Sweden reported an association between chronic HBV
infection and upper aerodigestive tract, lung, kidney, skin,
and thyroid gland cancers; lymphoma; and leukemia [16].
However, a case–control study in Shanghai, China, dem-
onstrated that patients with HBV had no risk of cancers of
the gallbladder, ampulla of Vater, and bile duct [17]. Over-
all, data on the association between CHI and extrahepatic
cancer development in countries with endemic HBV and
HCV infection are lacking. Previous studies have been
conducted in countries with low prevalence and endem-
icity; hence, drawing a statistically supported conclusion
from their results is difficult [15, 17, 18]. Moreover, these
studies have focused on the association of HBV or HCV
with primary liver cancer; comprehensive data on extrahe-
patic cancers among patients with CHI are lacking.
This longitudinal cohort study comprehensively inves-
tigated the association of CHI with extrahepatic cancer
development in Taiwan, using a nationwide population-
based data set. HBV infection is endemic and HCV in-
fection is highly prevalent in Taiwan [19]. In addition,
cancer is highly prevalent in Taiwan, making the country
an excellent setting for studying the association of CHI
with cancer.
Methods
Data sources
In this study, the Longitudinal Health Insurance
Database 2000 (LHID2000) of the National Health
Insurance (NHI) program, which was launched in March
1995 to provide affordable healthcare services to all resi-
dents of Taiwan, was used. The program covered 93 % of
the population in 1997, and the coverage rate increased to
approximately 99.9 % by the end of 2014. The National
Health Insurance Research Database (NHIRD) is a nation-
wide database extracted from the claims data of the NHI
program for research purposes. This database contains
information on inpatient and outpatient medical claims,
including prescription and diagnosis records.
The LHID2000, which is a data set of the NHIRD,
contains the claims data of one million beneficiaries ran-
domly selected from all of the residents enrolled in the
NHI program in 2000. No significant differences have
been observed in age, sex, or healthcare costs between
the entire population of this data set and all beneficiaries
of the NHI program. Approval to use all the claims data
and updated registries in the LHID2000 from 2000 to 2011
was received, and the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
was used to identify disease diagnoses in the NHIRD. All
data were anonymized upon inclusion in the NHIRD.
Notably, this study was exempted from full review by the
Institutional Review Board at China Medical University
and the Hospital Research Ethics Committee (IRB permit
number: CMU-REC-101-012).
Study sample
In this study, the association of CHI with hepatic and
extrahepatic cancer development among an adult popu-
lation (≥18 years old) was investigated. The etiologies of
other types of chronic hepatitis, such as autoimmune,
chemical, and alcohol-related hepatitis, and nonalcoholic
fatty liver disease, were excluded. Additionally, the
presence of HBsAg was used as the major serum marker
for cases of HBV infection recorded in the database.
Patients with a history of human immunodeficiency
virus (HIV) were excluded to minimize the inclusion of
patients with HBV/HIV coinfection with occult HBV in-
fection (i.e., HBsAg-negative patients with persistent
HBV infection) [20]. Therefore, patients with a history
of HIV (ICD-9-CM codes 042, 043, 044, V08, and 795.8)
and chronic hepatitis (ICD-9-CM codes 571.4, 571.8,
571.9, and 573.3) without mention of HBV (ICD-9-CM
codes 070.2, 070.3, and V02.61) or HCV (ICD-9-CM
codes 070.41, 070.44, 070.51, 070.54, and V02.62) infec-
tion were excluded. The index date for patients with
chronic HBV or HCV infection was the first date on
which chronic HBV or HCV infection was detected.
Patients with a diagnosis of cancer (ICD-9-CM codes
140–208) before the index date were also excluded.
After applying the exclusion criteria, 15,888 patients
with HBV infection (including 3,519 coinfected with
HCV) and 8,830 with HCV infection (including 3,519
coinfected with HBV), who were identified during 2000–
2005, were enrolled in this study as the CHI cohort and
followed up until cancer diagnosis or the end of 2011,
whichever occurred first. In total, 939,971 insurants
without hepatitis and with information on age and sex
were identified; after excluding those aged < 18 years
who had had HIV or cancer before the index date,
63,552 and 35,320 control participants were identified
and included in the non-HBV cohort and non-HCV co-
hort, respectively. The nonhepatitis cohorts were fre-
quency matched to the CHI cohort at a ratio of 4:1 by
age, sex, and index date and year (Fig. 1).
Patients newly diagnosed with head and neck cancer
(ICD-9-CM codes 140 and 149), esophageal cancer (ICD-
9-CM code 150), stomach cancer (ICD-9-CM code 151),
colorectal cancer (ICD-9-CM codes 153 and 154), liver
cancer (ICD-9-CM code 155), gallbladder and extrahe-
patic bile duct cancer (ICD-9-CM code 156), pancreatic
cancer (ICD-9-CM code 157), lung cancer (ICD-9-CM
code 162), melanoma (ICD-9-CM code 172), skin cancer
(ICD-9-CM code 173), breast cancer (ICD-9-CM codes
174 and 175), uterine and corpus cancer (ICD-9-CM
codes 179 and 182), cervical cancer (ICD-9-CM code
180), ovarian cancer (ICD-9-CM code 183), prostate can-
cer (ICD-9-CM code 185), bladder cancer (ICD-9-CM
code 188), kidney cancer (ICD-9-CM code 189), brain
cancer (ICD-9-CM code 191), thyroid cancer (ICD-9-CM
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code 193), non-Hodgkin’s lymphoma (ICD-9-CM code
202), myeloma (ICD-9-CM code 203), and leukemia
(ICD-9-CM codes 204 and 208) during 2000–2011 were
identified from the Registry of Catastrophic Illness
Patients. Insurance coverage for catastrophic illnesses is
an extension of the NHI program that protects people
with serious disease against a devastating financial burden
and subsequent impoverishment.
Statistical analyses
Pearson’s chi-square test was used to compare the distri-
butions of sociodemographic factors and various comor-
bidities, such as diabetes mellitus, hypertension, and
hyperlipidemia, between the CHI cohort and the nonhe-
patitis cohorts, and the Student t-test was used to com-
pare the number of outpatient visits between the CHI
cohort and the nonhepatitis cohorts. Urbanization was
categorized into four levels, with level 1 referring to the
most urbanized communities and level 4 to the least ur-
banized communities. The geographical regions where the
patients resided were divided into Northern Taiwan,
Central Taiwan, Southern Taiwan, Eastern Taiwan, and
the outlying islands. Additionally, the patients’ monthly
incomes were categorized into four groups: NT$0, NT$1–
NT$15,840, NT$15,841–NT$25,000, and > NT$25,000.
The cancer incidence rates were evaluated from the
initial follow-up to the end of 2011. The follow-up
period (years) was defined as the duration from chronic
viral hepatitis identification to cancer diagnoses or
censoring for death, emigration, or withdrawal from the
NHI program, whichever occurred first. Poisson regres-
sion was used to calculate the incidence rate ratios with
95 % confidence intervals (CIs) for comparison of our
HBV or HCV cohorts with the adult population in the
LHID2000. Finally, a Cox proportional hazard model
was used to calculate hazard ratios (HRs) and 95 % CIs
for determining the association between CHI and cancer
development. HRs were adjusted for sex, age, geograph-
ical region, occupation, level of urbanization, monthly
income, the presence of comorbidities, and number of
outpatient visits. A p value < 0.05 was considered statisti-
cally significant. All statistical analyses were performed
using SAS (Version 9.4 for Windows; SAS Institute, Inc.,
Cary, NC, USA).
Results
In our study, the patients with HBV infection were more
likely to be laborers, reside in Central and Southern Taiwan,
and have a higher monthly income, compared with the
patients without HBV infection (Table 1). Moreover, these
patients were more likely to have diabetes mellitus, hyperten-
sion, and hyperlipidemia. Similarly, the patients with HCV
infection were more likely to be laborers, reside in less ur-
banized areas in Southern Taiwan, and have comorbidities,
compared with the patients without HCV infection.
Table 2 presents the incidence densities of cancers
among the patients with CHI. The Poisson regression
model revealed that, compared with the adult population
Fig. 1 Flowchart of patient recruitment
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Table 1 Baseline characteristics and comorbid conditions in hepatitis cohorts identified in 2000–2005
HBV HCV
Variable No
n (%)
Yes
n (%)
X2 df p value No
n (%)
Yes
n (%)
X2 df P value
Sex 0.00 1 1.000 0.00 1 1.000
Women 26832 (42.2) 6708 (42.2) 16864 (47.7) 4216 (47.7)
Men 36720 (57.8) 9180 (57.8) 18456 (52.3) 4614 (52.3)
Age, years 0.00 3 1.000 0.00 3 1.000
< 50 45564 (71.7) 11391 (71.7) 17116 (48.5) 4279 (48.5)
50–59 9308 (14.6) 2327 (14.6) 7284 (20.6) 1821 (20.6)
60–69 5896 (9.3) 1474 (9.3) 6784 (19.2) 1696 (19.2)
≥ 70 2784 (4.4) 696 (4.4) 4136 (11.7) 1034 (11.7)
Geographical region 212.15 3 <0.0001 967.58 3 <0.0001
Northern 30226 (47.6) 6594 (41.5) 16176 (45.8) 2666 (30.2)
Central 12404 (19.5) 3401 (21.4) 6962 (19.7) 1882 (21.3)
Southern 16079 (25.3) 4698 (29.6) 9110 (25.8) 3597 (40.7)
Eastern and islands 4843 (7.6) 1195 (7.5) 3072 (8.7) 685 (7.8)
Occupation 118.28 4 <0.0001 277.96 4 <0.0001
Public 5956 (9.4) 1829 (11.5) 3519 (10.0) 758 (8.6)
Labor 19351 (30.4) 5159 (32.5) 12796 (36.2) 4010 (45.4)
Business 30002 (47.2) 7070 (44.5) 14066 (39.8) 2879 (32.6)
Low income 256 (0.4) 65 (0.4) 183 (0.5) 68 (0.8)
Retired 7987 (12.6) 1765 (11.1) 4756 (13.5) 1115 (12.6)
Urbanization level 94.02 3 <0.0001 428.06 3 <0.0001
1 (highest) 19662 (30.9) 4431 (27.9) 10499 (29.7) 1873 (21.2)
2 18754 (29.5) 4713 (29.7) 10162 (28.8) 2531 (28.7)
3 11896 (18.7) 2952 (18.6) 6314 (17.9) 1513 (17.1)
4 (lowest) 13232 (20.8) 3791 (23.9) 8340 (23.6) 2912 (33.0)
Monthly income, NT$ 79.93 3 <0.0001 127.57 3 <0.0001
0 13698 (21.6) 3282 (20.7) 8233 (23.3) 1869 (21.2)
1–15,840 7712 (12.1) 1633 (10.3) 4180 (11.8) 990 (11.2)
15,841–25,000 27135 (42.7) 6795 (42.8) 15717 (44.5) 4495 (50.9)
> 25,000 15007 (23.6) 4178 (26.3) 7190 (20.4) 1476 (16.7)
Diabetes mellitus 232.42 1 <0.0001 280.01 1 <0.0001
No 59599 (93.8) 14355 (90.4) 31531 (89.3) 7311 (82.8)
Yes 3953 (6.2) 1533 (9.6) 3789 (10.7) 1519 (17.2)
Hypertension 88.26 1 <0.0001 122.42 1 <0.0001
No 54129 (85.2) 13054 (82.2) 26215 (74.2) 6038 (68.4)
Yes 9423 (14.8) 2834 (17.8) 9105 (25.8) 2792 (31.6)
Hyperlipidemia 347.37 1 <0.0001 121.67 1 <0.0001
No 57936 (91.2) 13702 (86.2) 30422 (86.1) 7194 (81.5)
Yes 5616 (8.8) 2186 (13.8) 4898 (13.9) 1636 (18.5)
Outpatient visits, mean (SD) 12 (13) 16 (15) <0.0001a 14 (15) 21 (18) <0.0001a
X2 Chi-square test, df degree of freedom
at-test
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in the LHID2000, the patients with HBV or HCV infec-
tion exhibited an increased risk of liver cancer (HR: 12.89,
95 % CI: 11.9–13.9 or HR: 16.26, 95 % CI: 15.1–17.5, re-
spectively). In addition, HBV infection was associated with
an increased risk of developing thyroid gland cancer,
stomach cancer, colorectal cancer, gallbladder and extra-
hepatic bile duct cancer, pancreatic cancer, lung cancer,
kidney cancer, bladder cancer, uterine and corpus cancer,
ovarian cancer, prostate cancer, breast cancer, skin cancer,
non-Hodgkin’s lymphoma, and leukemia. Similarly, HCV
infection was associated with an increased risk of de-
veloping head and neck cancer, stomach cancer, colon
and rectum cancer, gallbladder and bile duct cancer,
pancreatic cancer, lung cancer, kidney cancer, bladder
cancer, uterine cancer, prostate cancer, skin cancer,
and non-Hodgkin’s lymphoma.
Compared with their corresponding nonhepatitis co-
horts, the overall adjusted HRs for the risk of various
cancers were 2.67 (95 % CI: 2.49–2.86) and 2.83 (95 %
CI: 2.63–3.05) for the HBV and HCV cohorts, res-
pectively (Table 3). Specifically, the patients with HBV
infection exhibited an increased risk of colorectal cancer
(HR: 1.36, 95 % CI: 1.09–1.70), liver cancer (HR: 21.47,
95 % CI: 18.0–25.6), gallbladder and extrahepatic bile
cancer (HR: 2.05, 95 % CI: 1.07–3.91), pancreatic cancer
(HR: 2.61, 95 % CI: 1.47–4.61), kidney cancer (HR: 1.72,
95 % CI: 1.10–2.68), ovarian cancer (HR: 2.31, 95 % CI:
1.21–4.39), and non-Hodgkin’s lymphoma (HR: 2.10,
95 % CI: 1.25–3.52). Further analysis revealed that HCV
was also a significant risk factor for liver cancer (HR:
25.10, 95 % CI: 20.9–30.2), gallbladder and extrahepatic
bile duct cancer (HR: 2.60, 95 % CI: 1.42–4.73), ovarian
cancer (HR: 5.15, 95 % CI: 1.98–13.4), and non-
Hodgkin’s lymphoma (HR: 2.30, 95 % CI: 1.34–3.96).
Furthermore, we analyzed our data after excluding
those with HBV/HCV coinfection. The patients with
Table 2 Incidence densities of cancers in patients diagnosed with chronic HBV and HCV infection
All LHID2000 HBV HCV
Cancer type Events Ratea Events Ratea IRRb (95 % CI) Events Ratea IRRb (95 % CI)
Overall 40213 36.59 1330 94.01 2.95 (2.80–3.12)* 1232 163.00 3.33 (3.15–3.53)
Brain cancer 509 0.46 7 0.49 1.13 (0.53–2.38) 7 0.93 1.61 (0.76–3.39)
Head and neck cancer 4079 3.71 66 4.67 1.23 (0.97–1.57) 48 6.35 1.43 (1.08–1.90)*
Thyroid gland cancer 1138 1.04 24 1.70 1.78 (1.19–2.67)* 13 1.72 1.53 (0.89–2.65)
Esophageal cancer 850 0.77 15 1.06 1.45 (0.87–2.42) 11 1.46 1.48 (0.82–2.68)
Stomach cancer 2247 2.04 32 2.26 1.42 (1.00–2.01)* 37 4.90 1.78 (1.28–2.46)*
Colorectal cancer 5890 5.36 104 7.35 1.69 (1.39–2.05)* 83 10.98 1.51 (1.21–1.87)*
Liver cancer 5293 4.82 770 54.43 12.89 (11.9–13.9)* 782 103.46 16.26 (15.1–17.5)*
Gallbladder and extrahepatic bile duct cancer 501 0.46 14 0.99 2.80 (1.64–4.76)* 18 2.38 3.81 (2.38–6.10)*
Pancreatic cancer 684 0.62 19 1.34 2.73 (1.73–4.31)* 17 2.25 2.66 (1.65–4.31)*
Lung cancer 4656 4.24 74 5.23 1.57 (1.25–1.97)* 69 9.13 1.61 1.27–2.04)*
Kidney cancer 1065 0.97 28 1.98 2.47 (1.70–3.60)* 17 2.25 1.71 (1.06–2.76)*
Bladder cancer 1324 1.20 24 1.70 1.83 (1.22–2.74)* 24 3.18 1.98 (1.33–2.97)*
Uterine and corpus cancerc 600 1.10 14 2.29 2.12 (1.25–3.61)* 11 2.98 2.17 (1.19–3.93)*
Cervical cancerc 1877 3.43 10 1.64 0.51 (0.27–0.95) 11 2.98 0.62 (0.34–1.12)
Ovarian cancerc 592 1.08 15 2.45 2.29 (1.37–3.82)* 8 2.16 1.67 (0.83–3.35)
Prostate cancerd 1820 3.30 30 3.73 1.83 (1.28–2.63)* 24 6.21 1.55 (1.04–2.32)*
Breast cancerc 4695 8.58 74 12.10 1.43 (1.14–1.80)* 46 12.45 1.17 (0.87–1.56)
Melanoma 136 0.12 0 – – – 2 0.26 1.58 (0.39–6.37)
Skin cancer 619 0.56 15 1.06 2.44 (1.46–4.08)* 11 1.46 1.90 (1.04–3.44)*
Non-Hodgkin’s lymphoma 738 0.67 22 1.56 2.58 (1.69–3.94)* 20 2.65 3.01 (1.93–4.69)*
Myeloma 218 0.20 2 0.14 0.87 (0.22–3.49) 3 0.40 1.47 (0.47–4.60)
Leukemia 682 0.62 15 1.06 1.82 (1.09–3.04)* 7 0.93 1.19 (0.56–2.50)
IRR incidence rate ratio
aPer 10,000 person-years
bAdjusted for sex and age
cWomen only
dMen only
*p< 0.05
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only HBV infection exhibited an increased risk of colo-
rectal cancer (HR: 1.51, 95 % CI: 1.15–1.98), liver cancer
(HR: 18.9, 95 % CI: 15.2–23.6), kidney cancer (HR: 1.81,
95 % CI: 1.10–3.01), and non-Hodgkin’s lymphoma (HR:
2.22, 95 % CI: 1.18–4.18), whereas the patients with
HCV exhibited an increased risk of liver cancer (HR:
23.28, 95 % CI: 18.4–29.5), gallbladder and extrahepatic
bile duct cancer (HR: 2.53, 95 % CI: 1.17–5.48), and
non-Hodgkin’s lymphoma (HR: 2.66, 95 % CI: 1.34–5.27)
(Table 4).
Discussion
The present population-based study revealed that CHI is
associated with an increased risk of extrahepatic cancer
in Taiwan. Approximately 15.4 % of the global cancer
burden can be attributed to five infectious agents,
namely Epstein–Barr virus, human papillomavirus, HBV,
HCV, and Helicobacter pylori [21]. HBV, an enveloped
DNA virus from the hepadnavirus family, has a high
affinity for hepatocytes. In Asia, where HBV infection is
highly endemic, vertical transmission is the main route
of HBV exposure. By contrast, HCV is an RNA virus
from the flavivirus family that is commonly transmitted
horizontally through contaminated blood, blood prod-
ucts, and intravenous drug use.
The association between CHI and primary liver cancer
has been extensively documented [7, 22–24], and in this
study, the patients with CHI exhibited an increased risk
of liver cancer. However, the mechanism by which hepa-
titis viruses cause liver cancer remains unclear. It has
been suggested that hepatitis viruses cause genomic in-
stability through integration into human chromosomes,
which causes the chromosomal rearrangement of cellu-
lar genes and increases the likelihood of hepatocarcino-
genesis [25]. Furthermore, patients with CHI are at an
increased risk of non-Hodgkin’s lymphoma [12–15]. In
this study, the patients with CHI exhibited a higher risk of
non-Hodgkin’s lymphoma than the nonhepatitis cohorts.
Table 3 Hazard ratios for developing cancer in patients with CHI
HBV HCV
No Yes No Yes
Cancer type Cases Cases HR (95 % CI)a Cases Cases HR (95 % CI)a
Overall 2,139 1,330 2.67 (2.49–2.86)‡ 1,893 1,232 2.83 (2.63–3.05)‡
Brain cancer 30 7 1.04 (0.45–2.39) 18 7 1.67 (0.68–4.15)
Head and neck cancer 288 66 0.96 (0.73–1.26) 171 48 1.13 (0.81–1.57)
Thyroid gland cancer 61 24 1.50 (0.93–2.42) 44 13 1.18 (0.62–2.24)
Esophageal cancer 54 15 1.42 (0.79–2.54) 46 11 1.24 (0.63–2.43)
Stomach cancer 132 32 1.11 (0.75–1.65) 122 37 1.41 (0.96–2.06)
Colorectal cancer 341 104 1.36 (1.09–1.70)† 327 83 1.07 (0.84–1.38)
Liver cancer 155 770 1.47 (18.0–25.6)‡ 137 782 25.10 (20.9–30.2)‡
Gallbladder and extrahepatic bile duct cancer 30 14 2.05 (1.07–3.91)* 32 18 2.60 (1.42–4.73)†
Pancreatic cancer 35 19 2.61 (1.47–4.61)† 55 17 1.51 (0.86–2.65)
Lung cancer 292 74 1.11 (0.86–1.44) 318 69 0.93 (0.71–1.21)
Kidney cancer 69 28 1.72 (1.10–2.68)* 68 17 0.99 (0.57–1.71)
Bladder cancer 80 24 1.24 (0.78–1.97) 87 24 1.20 (0.75–1.90)
Uterine and corpus cancerb 43 14 1.28 (0.69–2.37) 26 11 1.82 (0.87–3.78)
Cervical cancerb 62 10 0.74 (0.38–1.46) 62 11 0.81 (0.42–1.56)
Ovarian cancerb 27 15 2.31 (1.21–4.39)* 10 8 5.15 (1.98–13.4)†
Prostate cancerc 134 30 0.95 (0.64–1.42) 136 24 0.81 (0.52–1.27)
Breast cancerb 256 74 1.25 (0.96–1.62) 197 46 1.08 (0.78–1.50)
Melanoma 14 0 – – 12 2 0.78 (0.17–3.60)
Skin cancer 37 15 1.46 (0.79–2.69) 37 11 1.09 (0.54–2.17)
Non-Hodgkin’s lymphoma 45 22 2.10 (1.25–3.52)† 45 20 2.30 (1.34–3.96)†
Myeloma 12 2 0.93 (0.20–4.25) 13 3 1.15 (0.32–4.20)
Leukemia 43 15 1.44 (0.79–2.61) 25 7 1.21 (0.51–2.87)
*p < 0.05, †p < 0.001, ‡p < 0.0001
aAdjusted for sex, age, geographical region, occupation, level of urbanization, monthly income, the presence of comorbidities, and number of outpatient visits
bWomen only
cMen only
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This finding supports and extends previous reports of a
significant association between CHI and non-Hodgkin’s
lymphoma. Moreover, the patients with CHI exhibited an
increased risk of gallbladder and extrahepatic bile duct
cancer, which confirms that patients with CHI are at an
increased risk of cancer [11].
In addition to the well-established association between
CHI and primary liver cancer, our results indicated that
HBV infection is associated with an increased risk of
pancreatic cancer. However, the association was nonsig-
nificant after excluding the patients with HBV/HCV
coinfection. This observation is attributed to the small
sample size for pancreatic cancer; hence, statistical
power was decreased. The pancreas serves as a potential
reservoir of hepatitis viruses because of its close proxim-
ity to the liver, and the blood vessels and ducts it shares
with the liver [26]. Thus, the increased risk of pancreatic
cancer among the patients with HBV can be attributed
to these two factors. Moreover, previous meta-analyses
have reported an increased risk of pancreatic cancer
among patients with HBV infection [27, 28], which cor-
roborate our findings.
In the present study, other cancers such as kidney can-
cer, colorectal cancer, and ovarian cancer were also asso-
ciated with CHI. Sundquist et al. determined that there
was an increased incidence of kidney cancer among pa-
tients with HBV, substantiating our results [16]. Never-
theless, the increased risk of kidney cancer observed
here is a novel finding that requires further investigation.
Only a few studies have investigated the association be-
tween CHI and colorectal cancer, and they have reported
inconsistent findings [18, 29]. Rustagi et al. demon-
strated that HCV is an independent risk factor for colo-
rectal adenoma, and reported that HCV is associated
with a 2.04-fold higher risk of colorectal cancer [29]. By
contrast, in this study, we only observed this association
among the patients with HBV. In addition, previous
studies have suggested that X protein from HBV can
Table 4 Hazard ratios for developing cancer in patients with CHI after excluding HBV/HCV coinfected patients
HBV HCV
No Yes No Yes
Cancer type Cases Cases HR (95 % CI)a Cases Cases HR (95 % CI)a
Overall 1,517 829 2.34 (2.15–2.55)‡ 1,174 731 2.71 (2.47–2.99)‡
Brain cancer 21 4 0.85 (0.29–2.51) 13 4 1.51 (0.48–4.77)
Head and neck cancer 233 47 0.84 (0.61–1.16) 107 29 1.06 (0.70–1.62)
Thyroid gland cancer 53 20 1.41 (0.84–2.38) 23 9 1.62 (0.73–3.61)
Esophageal cancer 42 13 1.47 (0.78–2.76) 22 9 2.08 (0.93–4.65)
Stomach cancer 78 18 1.01 (0.60–1.69) 76 23 1.38 (0.85–2.24)
Colorectal cancer 212 72 1.51 (1.15–1.98)† 204 51 1.09 (0.79–1.49)
Liver cancer 102 439 18.9 (15.2–23.6)‡ 86 451 23.28 (18.4–29.5)‡
Gallbladder and extrahepatic bile duct cancer 20 7 1.56 (0.65–3.73) 19 11 2.53 (1.17–5.48)*
Pancreatic cancer 33 13 1.69 (0.88–3.23) 32 11 1.68 (0.82–3.41)
Lung cancer 198 48 1.07 (0.78–1.47) 212 43 0.87 (0.62–1.21)
Kidney cancer 52 22 1.81 (1.10–3.01)* 47 11 0.98 (0.49–1.93)
Bladder cancer 67 13 0.87 (0.48–1.58) 65 13 0.91 (0.50–1.68)
Uterine and corpus cancerb 33 11 1.26 (0.63–2.50) 25 8 1.61 (0.71–3.67)
Cervical cancerb 42 10 1.10 (0.55–2.21) 32 11 1.52 (0.75–3.08)
Ovarian cancerb 23 8 1.35 (0.60–3.07) 10 1 0.58 (0.07–4.62)
Prostate cancerc 96 22 0.93 (0.58–1.49) 82 16 0.84 (0.48–1.46)
Breast cancerb 192 53 1.15 (0.84–1.56) 92 25 1.24 (0.78–1.95)
Melanoma 11 0 – – 7 2 1.48 (0.29–7.56)
Skin cancer 27 13 1.90 (0.97–3.73) 24 9 1.35 (0.61–2.99)
Non-Hodgkin’s lymphoma 29 15 2.22 (1.18–4.18)* 27 13 2.66 (1.34–5.27)†
Myeloma 9 2 1.04 (0.22–4.90) 5 3 3.25 (0.73–14.5)
Leukemia 35 10 1.24 (0.61–2.52) 22 2 0.35 (0.08–1.53)
*p < 0.05, †p < 0.001, ‡p < 0.0001
aAdjusted for sex, age, geographical region, occupation, level of urbanization, monthly income, the presence of comorbidities, and number of outpatient visits
bWomen only
cMen only
Kamiza et al. BMC Cancer  (2016) 16:861 Page 7 of 9
bind and interfere with the components of the DNA re-
pair machinery and p53 tumor suppressor in response to
DNA damage, thereby increasing the risk of colorectal
cancer [18, 30]. In addition, the HBV X protein has been
reported to be highly expressed in the ovarian cancer
cells of Chinese women, implying that it may be in-
volved in the carcinogenesis of ovarian cancer [31].
However, the association between CHI and the afore-
mentioned cancers was nonsignificant after excluding
the patients with HBV/HCV coinfection, which reduced
the statistical power of the study.
By contrast, Mahale et al. and Lee et al. have argued
that there is an increased risk of head and neck, pros-
tate, and esophageal cancers among patients with HCV
[32, 33]. However, a nonsignificant association was ob-
served between CHI and these cancers in this study,
which is consistent with the findings of similar research
in the United States [34, 35]. This discrepancy can be at-
tributed to the control group selected by Mahale et al.,
which included patients diagnosed with lung, esopha-
geal, and urinary bladder cancers [32]. Moreover, the
novel findings reported by Lee et al. can be attributed to
the study’s small sample size for esophageal and prostate
cancers [33].
A major strength of the present study is that it analyzed
a large cohort of patients identified from the NHIRD, cov-
ering nearly the entire population of Taiwan. Only patients
diagnosed with HIV infection, alcohol-related hepatitis,
and autoimmune hepatitis were excluded, to prevent the
confounding effects of these diseases from skewing our re-
sults. However, this study has some limitations. First, the
NHIRD does not contain detailed information about pa-
tients’ smoking habits, alcohol consumption, family cancer
history, body mass index, nutritional status, environmen-
tal exposure to chemicals, or history of substance use;
therefore, we could not rule out the potential confounding
effects of these factors. Another limitation is the small
sample size for specific rare cancers, which reduced the
statistical power of this study.
Conclusions
In addition to the well-established association between
CHI and primary liver cancer, the present population-
based cohort study revealed that CHI is associated with
an increased risk of extrahepatic cancers of the colon
and rectum, gallbladder and extrahepatic bile ducts, pan-
creas, kidneys, and ovaries, as well as non-Hodgkin’s
lymphoma.
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